CA2395108A1 - Method of treating gastrointestinal tract disease with purinergic receptor agonists - Google Patents

Method of treating gastrointestinal tract disease with purinergic receptor agonists Download PDF

Info

Publication number
CA2395108A1
CA2395108A1 CA002395108A CA2395108A CA2395108A1 CA 2395108 A1 CA2395108 A1 CA 2395108A1 CA 002395108 A CA002395108 A CA 002395108A CA 2395108 A CA2395108 A CA 2395108A CA 2395108 A1 CA2395108 A1 CA 2395108A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
group
amino
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395108A
Other languages
English (en)
French (fr)
Inventor
Benjamin R. Yerxa
Janet L. Rideout
William Pendergast
Sammy R. Shaver
Zhen Zhang
Ward M. Peterson
Matthew Cowlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395108A1 publication Critical patent/CA2395108A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002395108A 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists Abandoned CA2395108A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17171099P 1999-12-22 1999-12-22
US60/171,710 1999-12-22
PCT/US2000/035439 WO2001045691A2 (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists

Publications (1)

Publication Number Publication Date
CA2395108A1 true CA2395108A1 (en) 2001-06-28

Family

ID=22624842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395108A Abandoned CA2395108A1 (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists

Country Status (9)

Country Link
EP (1) EP1261323A2 (ko)
JP (1) JP2003524636A (ko)
KR (1) KR20020069218A (ko)
CN (1) CN1413113A (ko)
AU (1) AU2603101A (ko)
BR (1) BR0016021A (ko)
CA (1) CA2395108A1 (ko)
MX (1) MXPA02005161A (ko)
WO (1) WO2001045691A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2003039473A2 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US6683060B2 (en) * 2002-02-25 2004-01-27 Advanced Gene Technology Corp. Matrix metalloproteinase and tumor necrosis factor inhibitors
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
KR101133944B1 (ko) * 2004-06-28 2012-04-13 아지노모토 가부시키가이샤 영양 조성물 및 소화관 기능 저하 예방?개선용 조성물
EP1806134B1 (en) * 2004-09-17 2012-07-11 Ajinomoto Co., Inc. Agent and food for preventing/improving functional digestive disorder
JP5408882B2 (ja) * 2008-01-23 2014-02-05 ヤマサ醤油株式会社 唾液分泌促進剤
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7395094A (en) * 1993-10-15 1995-05-04 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
PT981534E (pt) * 1997-02-06 2006-09-29 Inspire Pharmaceuticals Inc Dinucleotidos e suas utilizacoes
CA2359891A1 (en) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof

Also Published As

Publication number Publication date
WO2001045691A3 (en) 2002-04-18
EP1261323A2 (en) 2002-12-04
BR0016021A (pt) 2003-07-15
AU2603101A (en) 2001-07-03
JP2003524636A (ja) 2003-08-19
KR20020069218A (ko) 2002-08-29
MXPA02005161A (es) 2002-12-09
WO2001045691A2 (en) 2001-06-28
CN1413113A (zh) 2003-04-23

Similar Documents

Publication Publication Date Title
US6624150B2 (en) Method of treating gastrointestinal tract disease with purinergic receptor agonists
KR100606131B1 (ko) 디뉴클레오티드 및 그의 용도
US5837861A (en) Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
CA2395108A1 (en) Method of treating gastrointestinal tract disease with purinergic receptor agonists
CA2748057C (en) Nucleoside phosphoramidates
IL267291B2 (en) Actonucleotidase inhibitors and methods of using them
CA2352262A1 (en) Method of promoting cervical and vaginal secretions
US6864243B1 (en) Method for treating retinal degeneration with purinergic receptor agonists
US6555675B2 (en) Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
JP2005532254A (ja) 炎症性疾患を治療又は予防する方法
JPWO2018199048A1 (ja) ヌクレオシド系抗がん剤または抗ウィルス剤の５’位モノ燐酸ジベンジルエステル誘導体
WO2006016115A2 (en) Method and means for enhanced pulmonary drug delivery
JP2002528510A (ja) ＨＩＶ感染の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
MXPA99007236A (en) Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency

Legal Events

Date Code Title Description
FZDE Dead